

# WB-Validated CD36 Lentiviral shRNA Knockdown Kit



**Catalog #: V61381**

## Aliases

CD36; CD36 Molecule; GPIIIB; GPIV; GP3B; FAT; GP4; Platelet Glycoprotein 4; Fatty Acid Translocase; SCARB3; CD36 Antigen (Collagen Type I Receptor, Thrombospondin Receptor); CD36 Molecule (Thrombospondin Receptor); Leukocyte Differentiation Antigen CD36; Platelet Glycoprotein IV; Glycoprotein IIb; PAS IV; Scavenger Receptor Class B, Member 3; Scavenger Receptor Class B Member 3; Platelet Collagen Receptor; Thrombospondin Receptor; Cluster Determinant 36; PAS-4 Protein; CD36 Antigen; BDPLT10; CHDS7; PASIV; PAS-4

## Background

Gene Name: CD36

NCBI Gene Entry: [948](#)

## Storage

Store at -80 °C for one year.

## Kit Components

1. WB-Validated CD36 shRNA lentiviral particles (4 mL)
- 2 . Non-Target shRNA lentiviral particles (4 mL)
3. Verification Tool: KD-Validated Anti-CD36 Rabbit mAb #61381 (5 µL)

## Tested Cell Line

HeLa

## Validation Methods

RT-qPCR; Western Blotting (WB)

## Shipping

Shipped with dry ice. Immediately store the product in a standard freezer at -80°C upon receipt.

## Instructions For Use

The following protocol uses HeLa cell as an example assuming your cell culture medium is DMEM-based.

1. Release 0.5 million HeLa cells into a 35 mm tissue culture dish in 2 mL of the growth medium (DMEM containing 10% FBS and 1% pen/strep). Cell density should reach 50-60% confluence the following day.
2. 24 h after cell release, pre-warm the shRNA lentiviral medium to 37°C.

---

### SUPPORT

SUPPORT@GENUINBIOTECH.COM  
TEL: +1-540-855-7041

### ORDERS


SALES@GENUINBIOTECH.COM  
FAX: +1-540-855-7041

[WWW.GENUINBIOTECH.COM](http://WWW.GENUINBIOTECH.COM)

3. Discard 1 mL of the original growth medium of the 35 mm dish.
4. Using a serological pipette, gently mix the lentiviral solution 3 times.
5. Carefully add 1 mL of the lentiviral solution to the well. Tip: To prevent splashing, add the solution to the dish along the wall.
6. Add a polybrene stock solution to the culture medium at a final concentration of 5 µg/mL. Gently swirl the dish to mix.
7. 48 h after cell release, without discarding the original medium, add another 1 mL of lentiviral medium directly into the dish.
8. Add an additional polybrene stock solution into the dish to obtain a final concentration of 5 µg/mL. Tip: Now, the medium in the dish should be a total of 3 mL.
9. 72 h after cell release, cells may reach confluence. Trypsinize the cells off the 35 mm dish and culture those cells in a 60 mm dish.
10. Add puromycin to the dish at a final concentration of 4 µg/mL. Tip: To assess the efficacy of puromycin selection, culture a dish of wild-type HeLa cells as a negative control.
11. Allow puromycin selection for 48 h. Almost all wild-type HeLa cells should die, while the dish infected with lentiviruses should have some remaining cells.
12. Replace the medium with regular growth medium without puromycin and allow the cells to grow to confluence before harvesting or staining.

**Note:** 1. This product is for research use only.  
2. This product is only supplied to end users.  
3. Do not use this product for commercial.


### Validation Data



| Genotype                        | Ct Value |
|---------------------------------|----------|
| Wild-Type                       | 26.33    |
| Knock-Down                      | 33.47    |
| $\Delta Ct (Ct_{KD} - Ct_{WT})$ | 7.14     |
| % mRNA Reduction                | ↓ 99%    |

Copyright ©2024 Genuit Biotechnologies LLC

RT-qPCR analysis. HeLa cells were infected with CD36-specific shRNA lentiviral particles, total RNA was extracted from wild-type and knockdown cells, RT-qPCR was performed using gene-specific primers.  $\Delta Ct (Ct_{KD} - Ct_{WT})$  was used to calculate mRNA reduction (%) between wild-type and knockdown cells using the following formula:  $(1 - 1/2^{\Delta Ct}) \times 100\%$ .



Western blotting analysis. CD36 protein expression in wild-type (WT) and shRNA knockdown (KD) HeLa cells was detected using Western blotting.  $\beta$ -Tubulin served as a loading control. The blots were incubated with primary antibodies (Cat#61381, 1:5,000) against CD36 and  $\beta$ -Tubulin, respectively, followed by incubating with HRP-conjugated goat anti-rabbit secondary antibody (Cat#201, 1:20,000). Images were developed using FeQ™ ECL Substrate Kit (Cat#226).